IRAK4 and rheumatoid arthritis: In a phase 2b, multi-center, double-blind, randomized clinical trial for patients with RA inadequately treated with methotrexate, patients taking a reversible IRAK4 inhibitor had a greater decrease in clinical disease scores and inflammatory markers compared to the placebo group (22).